Skip to Main Content Skip to Main Content

HSC Medicine, Dentistry and Healthcare Sciences Current Awareness Bulletins: Big 4 Journals

Big 4 Journals current awareness bulletin

The BMJ, JAMA, The Lancet, New England Journal of Medicine

Frequency: weekly

Links to articles in the current and previous 2 issues of this bulletin are displayed below.

To access articles, click on displayed links, and log in with your Healthcare Library number and password if prompted. For guidance on logging in, please go to: https://healthcarelibrary.qub.ac.uk/LogginginonTrustdevices/

To receive email notifications about new issues of this bulletin, please email: richard.fallis@healthcarelibrary.qub.ac.uk

This bulletin is based on the equivalent bulletin produced by Bodleian Health Care Libraries:

6th October 2025

The BMJ: 6th October 2025

HPV positive oropharyngeal cancer

Non-invasive high frequency oscillatory ventilation for primary respiratory support in extremely preterm infants: multicentre randomised controlled trial

Prostate specific antigen retesting intervals and trends in England: population based cohort study

Seven reasons why GP consultations are getting more complex

When chest pain tells an emotional truth

JAMA: 7th October 2025

Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial

Diverticulitis: a review

Helicobacter pylori screening after acute myocardial infarction: the cluster randomized crossover HELP-MI SWEDEHEART trial

Myo-inositol supplementation to prevent pregnancy complications in polycystic ovary syndrome: a randomized clinical trial

The Lancet: 11th October 2025

A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial

The EAT–Lancet Commission on healthy, sustainable, and just food systems

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial

The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

New England Journal of Medicine: 9th October 2025

Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension

Idiopathic intracranial hypertension

Nexiguran ziclumeran gene editing in hereditary ATTR with polyneuropathy

Permethrin-treated baby wraps for the prevention of malaria

Randomized trial of targeted indoor spraying to prevent Aedes-borne diseases

29th September 2025

The BMJ: 29th September 2025

Atypical diabetic neuropathies

Commercial sunbeds should be banned in the UK

Delivering on the 10 year health plan for England

Insurance coverage and employment after Medicaid expansion with work requirements: quasi-experimental difference-in-differences study

Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists

Use of new CORE risk score to predict 10 year risk of liver cirrhosis in general population: population based cohort study

Why can’t we do anything about delirium?

Why older people are still excluded from health research—and what can be done

JAMA: no new issue this week
The Lancet: 4th October 2025

Budesonide–formoterol versus salbutamol as reliever therapy in children with mild asthma (CARE): a 52-week, open-label, multicentre, superiority, randomised controlled trial

Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial

The future of type 1 diabetes therapy

Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study

Shigellosis

New England Journal of Medicine: 2nd October 2025

Allergy or assumption of allergy — when to test for a penicillin allergy

Clesrovimab for prevention of RSV disease in healthy infants

Home-based care for hypertension in rural South Africa

Intravenous rehydration for severe acute malnutrition with gastroenteritis

Medical imaging and pediatric and adolescent hematologic cancer risk

Monoclonal gammopathy of undetermined significance

Targeting APOC3 with olezarsen in moderate hypertriglyceridemia

22nd September 2025

The BMJ: 22nd September 2025

Effect of BCG Danish and oral polio vaccine on neonatal mortality in newborn babies weighing less than 2000 g in India: multicentre open label randomised controlled trial (BLOW2)

First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study

Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis

Supporting my child with her medical care

Surviving the aid cuts: how countries are sustaining health services

JAMA: 23rd/30th September 2025

A fall prevention program integrated in primary health care for older people in rural China: the FAMILY cluster randomized clinical trial

Geroscience: a translational review

Partial heart transplant for congenital heart disease

Transparent reporting of observational studies emulating a target trial—the TARGET statement

Treating Alzheimer disease with antiamyloid therapies—the real-world experience grows

The Lancet: 27th September 2025

Alzheimer's disease outlook: controversies and future directions

Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG)

New landscape of the diagnosis of Alzheimer's disease

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2)

Treatment for Alzheimer's disease

Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

New England Journal of Medicine: 25th September 2025

Advancing diagnostic excellence through medical education in diagnostic equity

Apixaban for extended treatment of provoked venous thromboembolism

Digitoxin in patients with heart failure and reduced ejection fraction

Early tirofiban infusion after intravenous thrombolysis for stroke

Measurable residual disease–guided therapy for chronic lymphocytic leukemia

Disclaimer

The Healthcare Library cannot guarantee the correctness or completeness of the information in these bulletins. The information is subject to change and we cannot guarantee it will remain up-to-date. It is your responsibility to check the accuracy and validity of the information. These bulletins are the property of the Healthcare Library; please credit us if re-using or distributing content from them.